What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer?

The ASCO Post

 Key Points

• Worsening of menopause-specific quality of life was associated with early discontinuation of chemopreventive therapy with aromatase inhibitors.
• Worsening in vasomotor, sexual, physical, and psychosocial domains were each associated with early treatment discontinuation.

Study Details
In the MAP.3 trial, 4,560 high-risk postmenopausal women were randomized between 2004 and 2010 to receive exemestane at 25 mg or placebo for 5 years. The current analysis included 4,501 participants, who completed the Menopause-Specific Quality-of-Life Questionnaire (MENQOL) at study entry and at 6 months.